QuidelOrtho Corporation (QL1A)
Summary
QL1A Chart
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.37. This compares to earnings of $0.74 per share a year ago.
QuidelOrtho Corporation (QL1A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has QuidelOrtho Corporation ever had a stock split?
QuidelOrtho Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Brian J. Blaser CEO | XSTU Exchange | US2197981051 ISIN |
| US Country | 6,600 Employees | - Last Dividend | - Last Split | 1 Feb 1991 IPO Date |
Overview
QuidelOrtho Corporation specializes in providing a wide range of diagnostic testing solutions aimed at enhancing patient care and health management. The company organizes its operations through four main business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics, each focused on delivering innovative testing products and instrumentation across various healthcare settings. Established in 1979 and based in San Diego, California, QuidelOrtho has a global footprint, serving customers in North America, Europe, the Middle East, Africa, and China. The company leverages a mix of direct sales and distributor networks to reach its diverse customer base, which includes physician offices, hospitals, clinical laboratories, blood banks, and more, catering to both professional and over-the-counter diagnostic needs.
Products and Services
- Labs Business Unit
This division offers a comprehensive array of clinical chemistry laboratory instruments and tests for measuring bodily fluid chemicals pertinent to patient health evaluation and clinical management. It also provides immunoassay laboratory instruments and tests for detecting proteins associated with disease spread, immune responses, or organ function markers. Furthermore, the unit supplies specialized diagnostic solutions across various therapeutic areas to assist in disease detection and monitoring.
- Transfusion Medicine Business Unit
Specializing in ensuring safe blood transfusions, this unit produces immunohematology instruments and tests vital for blood typing and patient-donor compatibility. It also encompasses donor screening instruments and tests for identifying infectious diseases in blood and plasma donations, crucial for maintaining a safe blood supply.
- Point-of-Care Business Unit
This segment focuses on delivering rapid test results through instruments and tests designed for a range of point-of-care settings. These solutions are pivotal in making immediate clinical decisions, enhancing patient convenience and care quality by providing timely diagnostic information.
- Molecular Diagnostics Business Unit
At the forefront of molecular diagnostic technologies, this business unit offers advanced systems like polymerase chain reaction (PCR) thermocyclers, amplification systems, and sample-to-result molecular instruments. These products are targeted at syndromic infectious disease diagnostics, offering precise and rapid identification of pathogens to facilitate effective treatment planning.
